Cost Considerations in the Management of Nonobstructive Azoospermia in the United States.

PURPOSE OF REVIEW: To identify the principal cost drivers in U.S. management of NOA and evaluate evidence-based strategies—particularly the sequencing of mTESE and the surgical venue—that can lower out-of-pocket spending without compromising success RECENT FINDINGS: mTESE provides ≈10 % higher sperm-retrieval than conventional TESE but adds an additional US 9.6 k, almost 50 % less than synchronized “fresh” cycles because IVF fees are spared when no sperm are ultimately obtained. This savings, however, comes at a theoretical decrease in overall success given the attrition that occurs with sperm cryopreservation. Office-based TESE under local anaesthesia may minimize surgical charges by up to 90 % while maintaining satisfactory outcomes for the right patient. Surveys show 64 % of U.S. men still pay >US $15 k out-of-pocket, as state mandates rarely cover male procedures. Staging mTESE before IVF, shifting suitable cases to clinic settings, and using dynamic institutional cost models can markedly reduce financial barriers while preserving clinical efficacy, guiding value-based NOA care and policy.